Janus Henderson Group PLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

Janus Henderson Group PLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 16.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,317,710 shares of the company’s stock after selling 251,854 shares during the period. Janus Henderson Group PLC’s holdings in Novo Nordisk A/S were worth $169,192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of NVO. First PREMIER Bank acquired a new position in Novo Nordisk A/S in the first quarter valued at $25,000. CNB Bank acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $26,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $26,000. Orion Capital Management LLC acquired a new position in Novo Nordisk A/S in the first quarter valued at $26,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $30,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Argus boosted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, July 1st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Trading Up 0.9 %

Shares of Novo Nordisk A/S stock traded up $1.19 during mid-day trading on Tuesday, hitting $129.24. 4,384,123 shares of the stock were exchanged, compared to its average volume of 4,412,850. The stock has a market capitalization of $579.97 billion, a price-to-earnings ratio of 44.94, a price-to-earnings-growth ratio of 1.27 and a beta of 0.41. Novo Nordisk A/S has a twelve month low of $78.19 and a twelve month high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The company has a 50-day simple moving average of $138.59 and a 200 day simple moving average of $128.69.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.